- Home
- JBDI vs SPRB Comparison
JBDI vs SPRB Comparison
Compare JBDI & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBDI
- SPRB
- Stock Information
- Founded
- JBDI 1983
- SPRB 2014
- Country
- JBDI Singapore
- SPRB United States
- Employees
- JBDI N/A
- SPRB N/A
- Industry
- JBDI
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- JBDI
- SPRB Health Care
- Exchange
- JBDI Nasdaq
- SPRB Nasdaq
- Market Cap
- JBDI 14.0M
- SPRB 15.7M
- IPO Year
- JBDI 2024
- SPRB 2020
- Fundamental
- Price
- JBDI $0.60
- SPRB $0.38
- Analyst Decision
- JBDI
- SPRB Hold
- Analyst Count
- JBDI 0
- SPRB 7
- Target Price
- JBDI N/A
- SPRB $2.17
- AVG Volume (30 Days)
- JBDI 2.5M
- SPRB 552.0K
- Earning Date
- JBDI 02-15-2025
- SPRB 03-12-2025
- Dividend Yield
- JBDI N/A
- SPRB N/A
- EPS Growth
- JBDI N/A
- SPRB N/A
- EPS
- JBDI N/A
- SPRB N/A
- Revenue
- JBDI $9,394,000.00
- SPRB $7,101,000.00
- Revenue This Year
- JBDI N/A
- SPRB N/A
- Revenue Next Year
- JBDI N/A
- SPRB N/A
- P/E Ratio
- JBDI N/A
- SPRB N/A
- Revenue Growth
- JBDI N/A
- SPRB N/A
- 52 Week Low
- JBDI $0.51
- SPRB $0.34
- 52 Week High
- JBDI $39.41
- SPRB $5.95
- Technical
- Relative Strength Index (RSI)
- JBDI N/A
- SPRB 41.95
- Support Level
- JBDI N/A
- SPRB $0.35
- Resistance Level
- JBDI N/A
- SPRB $0.39
- Average True Range (ATR)
- JBDI 0.00
- SPRB 0.03
- MACD
- JBDI 0.00
- SPRB 0.00
- Stochastic Oscillator
- JBDI 0.00
- SPRB 36.60
About JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).